发明公开
EP3030264A1 BI-SPECIFIC MONOVALENT FC DIABODIES THAT ARE CAPABLE OF BINDING CD32B AND CD79B AND USES THEREOF
审中-公开
BISPEZIFISCHE MONOVALENTE FC-DIAKÖRPERZUR BINDUNG VON CD32B UND CD79B SOWIE VERWENDUNGEN DAVON
- 专利标题： BI-SPECIFIC MONOVALENT FC DIABODIES THAT ARE CAPABLE OF BINDING CD32B AND CD79B AND USES THEREOF
- 专利标题（中）： BISPEZIFISCHE MONOVALENTE FC-DIAKÖRPERZUR BINDUNG VON CD32B UND CD79B SOWIE VERWENDUNGEN DAVON
-
申请号： EP14834798.2申请日： 2014-08-06
-
公开(公告)号： EP3030264A1公开(公告)日： 2016-06-15
- 发明人: JOHNSON, Leslie S. , HUANG, Ling , SHAH, Kalpana , BONVINI, Ezio , MOORE, Paul A. , CHEN, Wei
- 申请人： MacroGenics, Inc.
- 申请人地址： 9640 Medical Center Drive Rockville, MD 20850 US
- 专利权人： MacroGenics, Inc.
- 当前专利权人： MacroGenics, Inc.
- 当前专利权人地址： 9640 Medical Center Drive Rockville, MD 20850 US
- 代理机构： Atkinson, Jennifer
- 优先权： US201361864217P 20130809; US201361866416P 20130815; US201361869519P 20130823; US201361907525P 20131122
- 国际公布： WO2015021089 20150212
- 主分类号： A61K39/395
- IPC分类号： A61K39/395
摘要：
The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain ("bi-specific monovalent Fc diabodies") and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a "CD32B x CD79b bi-specific monovalent Fc diabody"). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.
公开/授权文献
信息查询
